Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical company specializing in neurodegenerative disease therapies, has announced its participation in the upcoming Alzheimer’s Association International Conference (AAIC) scheduled for July 27–31, 2025, in Toronto. The company plans to present four scientific posters that will detail advancements in its Alzheimer’s clinical program, including the design of a Phase III trial, efficacy and safety data, and comparative pharmacokinetics of different formulations of its lead candidate, buntanetap, in both animals and humans.
The presentation of these findings at AAIC 2025 is significant for the medical and scientific communities, as it underscores Annovis Bio’s commitment to developing innovative treatments for neurodegenerative diseases. The data to be shared could have profound implications for the future of Alzheimer’s treatment, offering hope for improved therapies that target multiple neurotoxic proteins to restore brain function and enhance patients' quality of life.
For those interested in learning more about Annovis Bio’s research and developments, additional information is available at https://www.AnnovisBio.com. The company’s participation in AAIC 2025 represents a pivotal moment in its mission to combat neurodegenerative diseases and could mark a significant step forward in the global fight against Alzheimer’s.
